Business
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, held on December 9-10, 2025. Mr. Bagai’s presentation will be held on Tuesday, December
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIkpg_5WC5Ht6PAvrhd3Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, held on December 9-10, 2025. Mr. Bagai’s presentation will be held on Tuesday, December 9th at 12:30 P.M. ET.","length":527,"tagName":"p"},{"type":"text","content":"Mr. Bagai will share updates on RenovoRx’s continued commercial efforts and market traction, underscored by growing clinical demand and adoption of RenovoCath as a standalone, targeted drug-delivery device across both new and repeat customers. RenovoRx recently reported third quarter of 2025 financial results, demonstrating progress as year-to-date (end of September 30, 2025) revenue grew to approximately $900,000.","length":418,"tagName":"p"},{"type":"text","content":"He will also discuss recent advancements in the Company’s clinical research and scientific programs, including the ongoing Phase III TIGeR-PaC clinical trial for intra-arterial gemcitabine delivered via RenovoCath (IAG) in locally advanced pancreatic cancer (LAPC), and progress in its post-marketing registry study capturing real-world data on the safety and effectiveness of RenovoCath in patients with solid tumors. In addition, he will also highlight the ongoing support of investigator-initiated trials in borderline resectable and oligometastatic pancreatic cancer. These capital-efficient studies will provide meaningful data that create the potential to further broaden the application for RenovoRx’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform.","length":770,"tagName":...